Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -150.93
- Piotroski Score 1.00
- Grade Buy
- Symbol (AKTX)
- Company Akari Therapeutics, Plc
- Price $1.16
- Changes Percentage (-8.66%)
- Change -$0.11
- Day Low $1.10
- Day High $1.23
- Year High $4.40
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/19/2024
- Fiscal Year End N/A
- Average Stock Price Target $12,000.00
- High Stock Price Target $12,000.00
- Low Stock Price Target $12,000.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.14
- Trailing P/E Ratio -0.71
- Forward P/E Ratio -0.71
- P/E Growth -0.71
- Net Income $-10,008,000
